Core Viewpoint - The stock of Kaili Medical has experienced fluctuations, with a recent decline of 2.00% and a market capitalization of 12.72 billion yuan, indicating mixed investor sentiment and potential challenges in financial performance [1][2]. Financial Performance - For the period from January to September 2025, Kaili Medical reported a revenue of 1.459 billion yuan, reflecting a year-on-year growth of 4.37%. However, the net profit attributable to shareholders decreased significantly by 69.25% to 33.51 million yuan [2]. - The company has distributed a total of 381 million yuan in dividends since its A-share listing, with 258 million yuan distributed over the past three years [3]. Stock Performance and Trading Activity - As of November 12, the stock price of Kaili Medical was 29.40 yuan per share, with a trading volume of 68.17 million yuan and a turnover rate of 0.53%. The stock has seen a slight increase of 0.37% year-to-date, but a decline of 14.14% over the past 20 days [1]. - The net outflow of main funds was 1.90 million yuan, with large orders accounting for 10.58% of purchases and 13.37% of sales, indicating a cautious trading environment [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased by 12.75% to 16,100, while the average circulating shares per person decreased by 11.31% to 26,824 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 7.40 million shares, an increase of 1.72 million shares from the previous period, while the Hua Bao Zhong Zheng Medical ETF reduced its holdings by 1.07 million shares [3].

Core Viewpoint - The stock of Zhonghe Technology has experienced a decline of 2.02% on November 12, with a current price of 8.24 CNY per share and a total market capitalization of 5.573 billion CNY [1] Financial Performance - For the period from January to September 2025, Zhonghe Technology achieved a revenue of 1.446 billion CNY, representing a year-on-year growth of 31.47% [2] - The net profit attributable to the parent company was -46.216 million CNY, showing a year-on-year increase of 47.01% [2] - The company has distributed a total of 78.6801 million CNY in dividends since its A-share listing, with 10.0425 million CNY distributed in the last three years [3] Stock Market Activity - As of November 12, the stock has decreased by 4.96% year-to-date, but has increased by 3.00% over the last five trading days, 5.64% over the last twenty days, and 2.11% over the last sixty days [1] - The stock has seen a net outflow of 13.0438 million CNY in principal funds, with significant selling activity [1] Business Segments - Zhonghe Technology's main business segments include: - Rail transit signal systems (54.76% of revenue) - Monocrystalline silicon and its products (32.74%) - Automatic ticketing systems (9.01%) - Smart products (2.24%) - Others (1.25%) [1] Shareholder Information - As of September 30, the number of shareholders for Zhonghe Technology was 48,600, a decrease of 7.08% from the previous period, with an average of 13,847 circulating shares per shareholder, an increase of 7.62% [2]

Company Overview - Pursuit Pharmaceutical Technology Co., Ltd. is located at 500 Guangdong Road, World Trade Building, 23rd Floor, Huangpu District, Shanghai, established on February 22, 2013, and listed on May 17, 2022 [1] - The company specializes in technology development, transfer, consulting, and services within the pharmaceutical sector, with 100% of its revenue derived from service activities [1] Financial Performance - For the period from January to September 2025, Pursuit achieved a revenue of 609 million yuan, representing a year-on-year growth of 2.59%, and a net profit attributable to shareholders of 87.38 million yuan, up 20.92% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 40.77 million yuan [3] Stock Performance - As of November 12, the stock price of Pursuit was 45.88 yuan per share, with a market capitalization of 3.625 billion yuan [1] - The stock has increased by 70.81% year-to-date, but has seen a decline of 6.04% over the last five trading days [1] Shareholder Information - As of October 31, the number of shareholders was 8,576, a decrease of 0.14% from the previous period, with an average of 8,782 circulating shares per shareholder, an increase of 0.14% [2] - Notable shareholders include Noan Pioneer Mixed A (320003) as the fifth largest shareholder with 3.29 million shares, and Tianhong Medical Health A (001558) as the eighth largest shareholder with 961,000 shares, which decreased by 467,700 shares from the previous period [3] Market Activity - On November 12, the stock experienced a trading volume of 57.36 million yuan, with a turnover rate of 1.63% [1] - The net inflow of main funds was 1.08 million yuan, with large orders accounting for 16.99% of purchases and 15.11% of sales [1] Industry Classification - Pursuit is classified under the Shenwan industry as part of the pharmaceutical and biological sector, specifically in medical services and medical research outsourcing [1] - The company is associated with various concept sectors including margin financing, buybacks, small-cap stocks, hepatitis treatment, and medical devices [1]

Core Viewpoint - Kosen Technology's stock price has experienced fluctuations, with a year-to-date increase of 63.46% but a recent decline in the last five and twenty trading days [1] Company Overview - Kosen Technology, established on December 1, 2010, and listed on February 9, 2017, is located in Kunshan, Jiangsu Province. The company specializes in precision manufacturing processes such as die casting, forging, stamping, CNC, laser cutting, laser welding, MIM, and precision injection molding [2] - The company provides precision metal and plastic structural components for well-known clients including Apple, Amazon, Google, and Medtronic, serving industries such as consumer electronics, medical devices, automotive (including new energy vehicles), LCD panels, and electronic cigarettes [2] - The revenue composition of Kosen Technology includes 76.75% from consumer electronic products, 10.58% from new energy-storage business, 8.10% from medical surgical instrument components, 3.33% from other precision metal components, and 1.23% from other sources [2] Financial Performance - As of September 30, Kosen Technology had 94,300 shareholders, an increase of 27.57% from the previous period, with an average of 5,884 circulating shares per person, a decrease of 21.61% [2] - For the first nine months of 2025, Kosen Technology reported revenue of 2.453 billion yuan, a year-on-year decrease of 6.45%, while the net profit attributable to shareholders was -115 million yuan, reflecting a year-on-year increase of 50.94% [2] Dividend Information - Kosen Technology has distributed a total of 283 million yuan in dividends since its A-share listing, with cumulative distributions of 71.68 million yuan over the past three years [3]

11月12日，聚光科技盘中下跌2.04%，截至10:34，报15.88元/股，成交5734.96万元，换手率0.80%，总 市值71.26亿元。 资金流向方面，主力资金净流出1165.49万元，特大单买入114.47万元，占比2.00%，卖出1521.44万元， 占比26.53%；大单买入1416.36万元，占比24.70%，卖出1174.88万元，占比20.49%。 分红方面，聚光科技A股上市后累计派现6.30亿元。近三年，累计派现1.12亿元。 机构持仓方面，截止2025年9月30日，聚光科技十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股1381.53万股，相比上期减少518.92万股。睿远成长价值混合A（007119）位居第五大流通 股东，持股1085.88万股，相比上期增加242.09万股。诺安先锋混合A（320003）、汇添富医药保健混合 （470006）退出十大流通股东之列。 聚光科技今年以来股价涨6.01%，近5个交易日跌3.17%，近20日跌12.46%，近60日跌20.96%。 责任编辑：小浪快报 资料显示，聚光科技(杭州)股份有限公司位于浙江省杭州市滨江区阡陌路459号，成 ...

Core Points - The stock price of MacAudie dropped by 2.01% to 18.00 CNY per share as of November 12, with a market capitalization of 9.313 billion CNY [1] - The company has seen a year-to-date stock price increase of 3.21%, but a decline of 4.26% over the last five trading days [1] - MacAudie's main business segments include electrical products (60.06%), microscopes (25.64%), and medical products and services (14.30%) [1][2] Financial Performance - For the period from January to September 2025, MacAudie reported a revenue of 1.099 billion CNY, representing a year-on-year growth of 10.35% [2] - The net profit attributable to shareholders for the same period was 144 million CNY, reflecting a year-on-year increase of 17.86% [2] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 37,300, with an average of 13,828 circulating shares per person, a slight decrease of 0.09% [2] - The company has distributed a total of 347 million CNY in dividends since its A-share listing, with 129 million CNY distributed over the last three years [3] - Hong Kong Central Clearing Limited is now the seventh-largest circulating shareholder, increasing its holdings by 671,800 shares [3]

甘李药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：创新药、生物医 药、医疗器械、多肽药、基金重仓等。 截至9月30日，甘李药业股东户数9.47万，较上期增加22.53%；人均流通股5889股，较上期减少 17.81%。2025年1月-9月，甘李药业实现营业收入30.47亿元，同比增长35.73%；归母净利润8.18亿元， 同比增长61.32%。 11月12日，甘李药业盘中上涨2.03%，截至09:50，报65.41元/股，成交1.78亿元，换手率0.49%，总市值 390.70亿元。 资金流向方面，主力资金净流入897.83万元，特大单买入652.78万元，占比3.68%，卖出325.78万元，占 比1.83%；大单买入4254.96万元，占比23.96%，卖出3684.13万元，占比20.75%。 甘李药业今年以来股价涨51.74%，近5个交易日涨1.92%，近20日跌7.73%，近60日涨7.21%。 资料显示，甘李药业股份有限公司位于北京市通州区漷县镇南凤西一路8号，成立日期1998年6月17日， 上市日期2020年6月29日，公司主营业务涉及重组胰岛素类似物原料药及注射剂的研 ...

Core Viewpoint - Kanghong Pharmaceutical has shown a significant stock price increase of 69.79% year-to-date, with a recent market capitalization of 29.72 billion yuan, indicating strong investor interest and potential growth in the pharmaceutical sector [1][2]. Financial Performance - For the period from January to September 2025, Kanghong Pharmaceutical reported a revenue of 3.624 billion yuan, reflecting a year-on-year growth of 6.23%, while the net profit attributable to shareholders was 1.033 billion yuan, up by 6.08% [2]. - The company has distributed a total of 2.038 billion yuan in dividends since its A-share listing, with 1.04 billion yuan distributed over the past three years [3]. Shareholder Information - As of October 20, 2025, the number of shareholders for Kanghong Pharmaceutical increased to 24,900, a rise of 3.53%, while the average number of tradable shares per shareholder decreased by 3.41% to 27,592 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 28.007 million shares, an increase of 730,000 shares from the previous period [3].

Company Overview - Yunnan Yixintang Pharmaceutical Group Co., Ltd. is located in Kunming, Yunnan Province, and was established on November 8, 2000. The company was listed on July 2, 2014. Its main business involves retail and wholesale of pharmaceuticals, with revenue composition as follows: Western and Chinese medicines 75.03%, others 9.86%, traditional Chinese medicine 8.56%, and medical devices and disinfectants 6.55% [1][2]. Stock Performance - As of November 12, Yixintang's stock price increased by 2.02%, reaching 14.14 CNY per share, with a market capitalization of 8.28 billion CNY. The stock has risen 12.85% year-to-date, with a 5.52% increase over the last five trading days [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on May 23, where it recorded a net buy of -4.0951 million CNY [1]. Financial Performance - For the period from January to September 2025, Yixintang reported a revenue of 13.001 billion CNY, a year-on-year decrease of 4.33%, and a net profit attributable to shareholders of 269 million CNY, down 8.17% year-on-year [2][3]. Shareholder Information - As of September 30, 2025, Yixintang had 37,500 shareholders, an increase of 10.53% from the previous period. The average number of circulating shares per shareholder decreased by 9.53% to 10,596 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 22.3144 million shares, an increase of 3.74 million shares from the previous period. Several new institutional shareholders have entered the top ten list [3]. Dividend Distribution - Since its A-share listing, Yixintang has distributed a total of 2.023 billion CNY in dividends, with 764 million CNY distributed over the past three years [3].

Core Viewpoint - Jinfa Technology's stock price has shown significant volatility, with a year-to-date increase of 116.69% but a recent decline in the last five and twenty trading days [2][3]. Stock Performance - As of November 12, Jinfa Technology's stock price was 18.51 CNY per share, with a market capitalization of 48.804 billion CNY [1]. - The stock has experienced a 2.01% drop on the day, with a trading volume of 1.01 billion CNY and a turnover rate of 0.21% [1]. - Year-to-date, the stock has risen by 116.69%, but it has decreased by 2.48% in the last five trading days and 9.09% in the last twenty days [2]. Financial Performance - For the period from January to September 2025, Jinfa Technology reported a revenue of 49.616 billion CNY, representing a year-on-year growth of 22.62% [3]. - The net profit attributable to shareholders for the same period was 1.065 billion CNY, reflecting a year-on-year increase of 55.86% [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 395,400, up by 94.23% from the previous period [3]. - The average number of circulating shares per shareholder decreased by 47.77% to 6,662 shares [3]. Dividend Distribution - Since its A-share listing, Jinfa Technology has distributed a total of 6.740 billion CNY in dividends, with 1.136 billion CNY distributed in the last three years [4]. Institutional Holdings - As of September 30, 2025, the sixth-largest circulating shareholder is Penghua CSI Sub-Segment Chemical Industry Theme ETF, holding 31.6477 million shares as a new shareholder [4]. - The seventh-largest shareholder, Southern CSI 500 ETF, holds 30.709 million shares, having decreased its holdings by 599,900 shares compared to the previous period [4].